METASTATIC CLEAR CELL RENAL CELL CARCINOMA
Clinical trials for METASTATIC CLEAR CELL RENAL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CLEAR CELL RENAL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC CLEAR CELL RENAL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a Pre-Surgery drug tame metastatic kidney cancer?
Disease control OngoingThis phase 2 trial is studying whether giving the drug sunitinib before surgery to remove a kidney can help control metastatic renal cell carcinoma. About 50 patients with kidney cancer that has spread will take sunitinib for 28 days, then have the affected kidney removed. Resear…
Matched conditions: METASTATIC CLEAR CELL RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New combo therapy aims to shrink kidney tumors before surgery
Disease control OngoingThis early-phase study tests whether giving immunotherapy drugs (nivolumab alone or with bevacizumab or ipilimumab) before surgery is safe for people with advanced kidney cancer that has spread. About 104 participants will receive one of these treatments before their tumor is rem…
Matched conditions: METASTATIC CLEAR CELL RENAL CELL CARCINOMA
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug duo takes on tough cancers
Disease control OngoingThis early-stage trial tests a new drug (DS3201) combined with an immunotherapy (ipilimumab) in people whose prostate, bladder, or kidney cancer has spread. The main goals are to find the safest dose and see what side effects occur. About 65 participants will receive both drugs t…
Matched conditions: METASTATIC CLEAR CELL RENAL CELL CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Engineered immune cells take on kidney cancer in early trial
Disease control OngoingThis early-phase study tests a new gene therapy for people with advanced clear cell kidney cancer. Doctors take a patient's own white blood cells, modify them in the lab to better attack cancer, and return them to the body. The main goals are to check safety and see if tumors shr…
Matched conditions: METASTATIC CLEAR CELL RENAL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New drug combo aims to shrink metastatic kidney tumors
Disease control OngoingThis study tests whether adding entinostat to high-dose aldesleukin (interleukin-2) can help shrink tumors in people with metastatic kidney cancer. About 47 adults with clear cell renal cell carcinoma that has spread will receive both drugs. The goal is to find the safest dose an…
Matched conditions: METASTATIC CLEAR CELL RENAL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New Dual-Action drug shows promise for kidney cancer patients
Disease control ENROLLING_BY_INVITATIONThis study tests a new medicine called AK112 (Yivoximab) for people with advanced kidney cancer that has spread. The drug works in two ways: it helps the immune system attack cancer cells and blocks blood vessels that feed tumors. About 60 participants will receive the drug every…
Matched conditions: METASTATIC CLEAR CELL RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Smart dosing of immunotherapy combo shows promise for kidney cancer
Disease control TerminatedThis phase II trial tests whether adjusting doses of two drugs—pembrolizumab (Keytruda) and axitinib (Inlyta)—based on tumor response can better control advanced kidney cancer. The study aims to enroll 75 adults with clear cell renal cell carcinoma that has spread. The trial is c…
Matched conditions: METASTATIC CLEAR CELL RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Gut bacteria booster may help kidney cancer drugs work better
Disease control OngoingThis early-phase trial is testing whether adding a probiotic called CBM588 to the standard combination of cabozantinib and nivolumab can improve treatment for advanced or metastatic kidney cancer. The probiotic is designed to restore helpful gut bacteria that may help the immune …
Matched conditions: METASTATIC CLEAR CELL RENAL CELL CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New hope for kidney cancer: which drug combo works best after immunotherapy fails?
Disease control OngoingThis study tests two different drug treatments in people with advanced kidney cancer that has spread and continued to grow despite prior immunotherapy. About 90 participants will receive either a combination of lenvatinib and everolimus or cabozantinib alone. The goal is to see w…
Matched conditions: METASTATIC CLEAR CELL RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug combo shows promise for untreated kidney cancer
Disease control OngoingThis study tests two drugs, pazopanib and bevacizumab, given one after the other in people with advanced kidney cancer that has spread. The goal is to find the best dose and see how well the combination works. About 51 patients who have not had prior treatment will take part. The…
Matched conditions: METASTATIC CLEAR CELL RENAL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New drug duo aims to outsmart advanced kidney cancer
Disease control TerminatedThis Phase 2 trial is testing a new combination of two immunotherapy drugs, botensilimab and balstilimab, against the standard combination of ipilimumab and nivolumab for people with advanced kidney cancer that has spread. The study plans to enroll 120 patients who have not had p…
Matched conditions: METASTATIC CLEAR CELL RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: Michael B. Atkins, MD • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New Dual-Action drug targets Hard-to-Treat kidney cancer
Disease control TerminatedThis early-stage study tests a new drug called NYM096 in people with advanced clear cell kidney cancer that has spread. The study has two parts: first, using a low dose to see if it can light up tumors on scans, and second, giving higher doses to see if it can shrink tumors and f…
Matched conditions: METASTATIC CLEAR CELL RENAL CELL CARCINOMA
Phase: PHASE1 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC